

Supplementary Figure S1. mi-21 levels upon plating, throughout passaging, and after serum restriction.


DAPI
FITC
OVERLAY
Nontransfected Cells
0.05 μM
0.1 μM
Inhibitor
Scramble
Inhibitor
Scramble
DAPI
FITC
OVERLAY
0.5 μM
1 μM
Inhibitor
Scramble
Inhibitor
Scramble
DAPI
FITC
OVERLAY

(A)


DAPI
FITC
OVERLAY
Nontransfected Cells
0.05 µM
0.1 µM
Inhibitor
Scramble
Inhibitor
Scramble
DAPI
FITC
OVERLAY
0.5 µM
1 µM
Inhibitor
Scramble
Inhibitor
Scramble
DAPI
FITC
OVERLAY

(B)

(C)



Supplementary Figure S2. Additional Confocal microscopy of LNAs at (A) 6 and (B) 24hrs with (C) number of fluorescent cells


(A)
0.1 µM
0.05 µM
Nontransfected Control
Scramble
Inhibitor
Scramble
Inhibitor
Q4 85,0
Q3 15,0
Q4 79,6
Q3 20,4
Q4 95,9
Q3 4,14
Q4 95,7
Q3 4,32
Q4 100,0
Q3 0,033
1 µM
0.5 µM
Scramble
Inhibitor
Scramble
Inhibitor
Q4 26,3
Q3 73,7
Q4 21,2
Q3 78,8
Q4 37,3
Q3 62,7
Q4 21,3
Q3 78,7



(B)

Supplementary Figure S3. Additional Flow Cytometry of LNAs at (A) 6 and (B) 24hrs.



Supplementary Figure S4. Original PTEN blot after miR-21 LNA and BPA treatment.





Supplementary Figure S5. Optimal reference gene selection (A) and number of references (B) across treatments using geNorm.